In the ALEX study, first-line treatment with alectinib prolonged the median PFS of ALK-positive NSCLC patients to 34.8 months compared to 9.3 months in the crizotinib-treated arm. The gene discussed is ALK; the disease is non-small cell lung carcinoma.